(Celltrion Healthcare)

Celltrion saw the combined market share of its autoimmune biosimilar infliximab products, Remsima and Remsima SC, rising in five European nations, company officials said Tuesday.

The combined market share of Remsima and the subcutaneous version of the drug hit 74 percent in Britain, Germany, France, Spain and Italy in the fourth quarter of last year, Celltrion said, citing data from health care researcher IQVIA.

The fourth-quarter tally was up 12 percentage points from the corresponding tally for 2020, when Remsima SC was released.

Remsima references Janssen Biotech Inc.'s Remicade and is effective in treating various diseases, from rheumatoid arthritis to Crohn's disease. (Yonhap)